Special articleWhy Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?
Section snippets
Should Cancer Drug Prices Be Determined by Market Forces or by Fair Pricing?
This trend of unaffordable cancer drug prices brought into question the justum pretium, the “just price” (or fair price) of a cancer drug vs “what the market bears.”5, 6 In a New York Times editorial, Paul Krugman7 relates the story of the Middle Ages Crusades to conquer the Holy Land being considered as Deus vult—“God wills it!” Today, the free market (a modern god) will offer, through its forces, the best economic solution—mercatus vult, “the market wills it.” We know today the consequences
Moral and Social Corporate Responsibilities of Pharmaceutical Companies When Establishing Cancer Drug Prices
George W. Merck, onetime president of the large pharmaceutical company Merck & Co. and the son of the founding family, said “Medicine is for the people. It is not for the profits.”14 Dr Rashi Fein said, “Decent people—and we are decent people—are offended by unnecessary pain and suffering; that is, by pain and suffering for which there is a treatment….”15 These views reflected historically the mission and vision of pharmaceutical companies, whose aims were to develop treatments that help
Unaffordable Cancer Drug Prices May Harm Patients
With out-of-pocket expenses of 20% to 30%, the financial burden for a patient with cancer for one drug would be $20,000 to $30,000 a year, nearly half of the average annual household income in the United States (about $52,000 in 2013).4 This financial burden is worse for seniors who rely on Medicare (average annual income per person, $23,500), and these are the individuals who are more likely to have cancers.16 About 10% to 20% of patients may decide to compromise on their therapy or to not
Should Oncologists Be Involved in This Discussion?
Physicians are bound by the Hippocratic Oath, which emphasizes 2 important tenets: protecting patients from harm and injustice both at the personal and social level. High drug prices make them unaffordable and inaccessible, thus causing harm to patients and injustice when differential therapies are applied on the basis of affordability. Oncologists thus have a moral obligation to advocate for affordable cancer drugs.
Justifications for High Cancer Drug Prices—Are the Reasons Offered Valid?
Pharmaceutical companies and their spokespersons routinely justify high prices with 4 arguments: (1) high cost of research and drug development, (2) comparative benefits to patients, (3) mercatus vult—market forces will settle prices to reasonable levels, and (4) controlling prices stifles innovation. We believe that none of the 4 reasons, offered after every protest about the announced shocking price of a new cancer drug, are convincing or ethically justifiable.
First, an objective evaluation
Americans Pay More for Cancer Drugs Than Populations Anywhere Else
The foregoing discussion brings into question the unfair burden of high drug prices paid by Americans vs the rest of the world. Although 85% of cancer basic research is funded through taxpayers’ money (drug companies spend only 1.3% revenues on basic research, net of taxpayers’ subsidies of company research and development costs), Americans with cancer still pay 50% to 100% more for the same patented drug than patients in other countries despite the fact that much of the research is subsidized
Factors That Perpetuate High Cancer Drug Prices
Is there a clear trigger for the recent skyrocketing of cancer drug prices? Influenced by the pharmaceutical lobby, the 2003 Medicare Prescription Drug, Improvement, and Modernization Act introduced legislation that forbade Medicare from negotiating drug prices.28 In addition, the Medicare expansion in 2006 included prescription drug benefits (Medicare Part D). This change resulted in drug companies and distributors being the only parties that decide the prices of the drugs that must be
Possible Solutions
Potential solutions to control and reduce cancer drug prices include the following: (1) allow Medicare to negotiate drug prices, (2) develop cancer treatment pathways/guidelines that incorporate the cost-benefit of cancer drugs (drug “value”), as occurs today in many other countries,41, 42, 43, 44 (3) allow the US Food and Drug Administration or physician panels to recommend target prices based on the magnitude of benefit (value-based pricing), as is practiced in many other developed countries,
References (46)
- et al.
The high cost of cancer drugs and what we can do about it
Mayo Clin Proc
(2012) - et al.
Variations in amenable mortality—trends in 16 high-income nations
Health Policy
(2011) - et al.
In cancer care, cost matters [op-ed]
New York Times
(October 15, 2012) The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts
Blood
(2013)- et al.
Market spiral pricing of cancer drugs
Cancer
(2013) - Household income in the United States. Wikipedia website....
- et al.
Cancer drugs in the United States: justum pretium—the just price
J Clin Oncol
(2013) - Krugman P. What markets will [op-ed]. New York Times, International Section, Review. October 18-19,...
- et al.
High cancer drug prices in the United States: reasons and proposed solution
J Oncol Pract
(2014) Does the United States have the best health-care system in the world?
ASCO Post
(2014)
Mirror, Mirror on the Wall, 2014 Update: How the U.S. Health Care System Compares Internationally
The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience
Oncologist
Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia
J Clin Oncol
Demythologizing the high costs of pharmaceutical research
Biosocieties
Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing
J Clin Oncol
The Price of Inequality: How Today’s Divided Society Endangers Our Future
Cited by (93)
The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis
2023, The Lancet Regional Health - Western PacificThe influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA
2022, The Lancet HaematologyCitation Excerpt :Conversely, the wholesale acquisition cost of the generic imatinib by Mylan Pharmaceuticals is $4400 and the average wholesale price is $5300, only 20% higher, and still only 4% of the average wholesale price of the other generics. This example is unfortunately only one facet of the dysfunctional health-care and drug-pricing systems in the USA.13–27 In the USA, different cost-reducing methods are often used, like applying to foundations for patient assistance (eg, Leukemia Lymphoma Society and HealthWell Foundation), using drug coupons (eg, GoodRx) that can reduce the monthly cost of imatinib 400 mg from up to $11 842 (table 1) to $114–800 (depending on the pharmacy), or accessing assistance directly from the manufacturer.
A vision: In silico clinical trials without patients
2020, Innovation in Clinical Trial Methodologies: Lessons Learned during the Corona PandemicThe High Cost of Insulin in the United States: An Urgent Call to Action
2020, Mayo Clinic ProceedingsCosts and Benefits of Branded Drugs: Insights from Cost-Effectiveness Research
2022, Journal of Benefit-Cost Analysis